Avasimibe Pfizer.

John R, Burnett; Murray W, Huff

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2003

Data sources: Europe PubMed Central

Avasimibe Pfizer.

descriptionPublicationkeyboard_double_arrow_right Article 27 May 2003 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 3 (issn: 1472-4472,

Copyright policy )

Authors: John R, Burnett; Murray W, Huff;

pmid: 12498009

Avasimibe Pfizer.

- Summary
- Subjects
- Metrics

Abstract

Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].

Related Organizations

Royal Perth Hospital
Australia

Keywords

Clinical Trials as Topic, Sulfonamides, Drug Industry, Arteriosclerosis, Hyperlipidemias, Acetates, Acetamides, Animals, Humans, Enzyme Inhibitors, Sulfonic Acids

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average